Vimta Labs Limited — Others, 06-06-2025: Amendment to AOA/MOA

Vimta Labs has revised the remuneration of its Managing Director and two Executive Directors, indicating a strategic alignment of leadership incentives. The company also expanded its business scope to include contract research and development (CDMO) services in pharmaceuticals, biotechnology, biopharmaceuticals, and medical sciences. New objectives cover R&D and manufacturing of biologics, biosimilars, peptides, and complex generics, reflecting Vimta’s focus on growth and diversification in advanced life sciences and pharma services, which could enhance its competitive position and long-term value for shareholders.